Nuvalent Inc.

This study tests a new drug called NVL-655 in people with advanced ALK-positive lung cancer or other solid tumors. The goal is to find the best dose and see how well it shrinks tumors. About 840 adults will take part, and the drug is taken as a pill.

This expanded access program provides zidesamtinib, an investigational drug, to adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have already tried at least one ROS1-targeted therapy and have no satisfactory alternatives. The goal is to offe…

This expanded access program offers the investigational drug neladalkib to adults with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have no satisfactory treatment options and cannot join a clinical trial. Participants must have already t…

This early-stage study tests an experimental drug called NVL-330 in people with advanced lung cancer that has specific changes in the HER2 gene. The main goals are to find a safe dose and see if the drug can shrink tumors. About 200 adults with this type of lung cancer will take …

This study tests a new drug called zidesamtinib (NVL-520) in people with advanced lung cancer or other solid tumors that have a specific genetic change called ROS1. The goal is to find the best dose and see how well the drug shrinks tumors. About 359 adults will take part, and th…

This phase 3 study compares a new drug, NVL-655, to the current standard alectinib in people with ALK-positive advanced non-small cell lung cancer who have not had prior treatment. The main goal is to see if NVL-655 can delay cancer growth or death longer than alectinib. About 45…